BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 17131404)

  • 1. Current approaches to medullary thyroid carcinoma, sporadic and familial.
    Fialkowski EA; Moley JF
    J Surg Oncol; 2006 Dec; 94(8):737-47. PubMed ID: 17131404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
    Quayle FJ; Moley JF
    J Surg Oncol; 2005 Mar; 89(3):122-9. PubMed ID: 15719378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma.
    Allen SM; Bodenner D; Suen JY; Richter GT
    Laryngoscope; 2009 Jul; 119(7):1303-11. PubMed ID: 19444888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medullary thyroid carcinoma.
    Pacini F; Castagna MG; Cipri C; Schlumberger M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.
    Frank-Raue K; Rondot S; Raue F
    Mol Cell Endocrinol; 2010 Jun; 322(1-2):2-7. PubMed ID: 20083156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current management of medullary thyroid cancer.
    Sippel RS; Kunnimalaiyaan M; Chen H
    Oncologist; 2008 May; 13(5):539-47. PubMed ID: 18515739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medullary thyroid carcinoma: state of the art.
    Favia G; Iacobone M
    G Chir; 2005; 26(11-12):405-9. PubMed ID: 16472416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature].
    de Groot JW; Links TP; Rouwe CW; van der Wal JE; Hofstra RM; Plukker JT
    Ned Tijdschr Geneeskd; 2006 Feb; 150(6):311-8. PubMed ID: 16503023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
    Fitze G; Saeger HD; Roesner D; Schackert HK
    Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].
    Frank-Raue K; Heimbach C; Rondot S; Usadel KH; Meng W; Varma C; Fuchs-Hammoser R; Höppner W; Schulze E; Raue F
    Dtsch Med Wochenschr; 2003 Sep; 128(39):1998-2002. PubMed ID: 14508694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
    Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
    Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple endocrine neoplasia type 2: 2007 update.
    Raue F; Frank-Raue K
    Horm Res; 2007; 68 Suppl 5():101-4. PubMed ID: 18174721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes.
    Spinelli C; Di Giacomo M; Costanzo S; Elisei R; Miccoli P
    J Pediatr Surg; 2010 Aug; 45(8):1610-6. PubMed ID: 20713208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
    Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
    Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
    Frank-Raue K; Rondot S; Schulze E; Raue F
    Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.